PCSK9 and familial hyperaldosteronism: The development of new experimental molecules such as proprotein convertase subtil-isin/kexin type 9 inhibitors (PCSK9i) [70] and association therapy based on monoclonal antibodies (mAbs) targeting PCSK9, evolocumab and alirocumab for treatment of patients diagnosed with heterozygous FH (HeFH) or both in the most severe homozygous FH (HoFH) has offered promising results in clinical trials [71].